Pre-Open Movers 07/23: (CBAY) (NTGR) (HZO) Higher; (LLNW) (ALGN) (MSFT) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Twitter, Inc. (TWTR) PT Raised to $40 at Canaccord Genuity
July 24, 2020 8:08 AM EDTCanaccord Genuity analyst Maria Ripps raised the price target on Twitter, Inc. (NYSE: TWTR) to $40.00 (from $32.00) while maintaining a Hold rating following the company's 2Q. Twitter's Q2 results showed a continued acceleration of user growth, up to a record~34% y/y (vs. +24% in Q1),... More
Twitter, Inc. (TWTR) PT Raised to 'Street High' $50 at Susquehanna
July 24, 2020 6:25 AM EDTSusquehanna analyst Shyam Patil raised the price target on Twitter, Inc. (NYSE: TWTR) to a 'Street High' $50.00 (from $35.00) while maintaining a Positive rating with mDAUs impress and ad revenue recovery better than feared.
Patil commented, "TWTR continues to see a gradual... More
MarineMax (HZO) PT Raised to $30 at Wedbush
July 23, 2020 3:37 PM EDTWedbush analyst James Hardiman raised the price target on MarineMax (NYSE: HZO) to $30.00 (from $23.00) while maintaining a Neutral rating.
Boat Sales Leap Past Even Raised Expectations... MoreCantor Fitzgerald Said 'Just the Beginning' of CymaBay Therapeutic (CBAY) Share Recovery After FDA Hold Lifted
July 23, 2020 10:35 AM EDTCantor Fitzgerald analyst Eliana Merle reiterated an Overweight rating and $15.00 price target on CymaBay Therapeutic (NASDAQ: CBAY) after the clinical hold on seladelpar was lifted. The analyst thinks this is just the beginning of a major recovery for shares.
Merle commented, "This morning CBAY announced the FDA lifted the clinical hold on seladelpar across all indications (PBC, PSC, NASH). This is a... More
